See Our Traction

Discover how our company is making significant progress in developing treatments for metabolic diseases.

ReRx Development Timeline

Since our inception, we have achieved significant milestones in drug discovery and validation, patent filings, and partnerships. Our commitment to advancing metabolic disease therapeutics have led to breakthroughs in reshaping the future of metabolic disease therapeutics.

Our leading indication from our lead candidate, ReRx-001 is addressing obesity with expansion to associated co-morbidities such as fatty liver disease, metabolic syndrome, and Type 2 diabetes. Through strategic collaborations and discovery approaches, we are continuing to develop novel therapeutic approaches to address severe metabolic diseases.

Trusted by industry-leading institutions


ReRx Awards History

Berkeley SkyDeck Cohort 17 Company
(Nov 2023 – present)
Berkeley Robinson (LSBE) Program Senior Capstone Partner Company
(August 2023 – December 2023)
Nucleate Bay Area Best Pitch Showcase Winner (May 2023)
Alnylam Pharmaceuticals Regional Scientific Excellence Award (May 2023)
Berkeley Life Science Entrepreneurship Center (LSEC) Sponsored Award
(May 2023)